28 August
2024
Polarean Imaging
plc
("Polarean" or the "Company")
Appointment of Chase Hall,
M.D., as Chief Medical Advisor
Adds significant pulmonary
expertise to help drive engagement with the medical
community
Polarean Imaging plc (AIM: POLX), a
commercial-stage medical device leader in advanced Magnetic
Resonance Imaging ("MRI") of lung function, announces that it has
appointed Chase Hall, M.D., as Chief Medical Advisor.
Dr. Hall is an Associate Professor,
Pulmonary, Critical Care and Sleep Medicine, at the University of
Kansas Medical Center in the Division of Pulmonary and Critical
Care. He also serves as Associate Director at the University of
Kansas Interstitial Lung Disease and Rare Lung Disease Clinic. Dr.
Hall's research focus has been on establishing imaging biomarkers
in respiratory disease, utilising Xenon MRI. In his lab, he is
currently working to utilise Xenon MRI as a sensitive measure of
treatment response in a number of respiratory diseases, as well as
rapid image acquisition protocols and fully automated image
analysis programmes. In addition, Dr. Hall is a member of the Xenon
MRI Clinical Trials Consortium, a growing collaboration of 13
clinical research sites; its activities include the harmonisation
and standardisation of Xenon imaging protocols for multi-center
clinical trials, training of new sites establishing Xenon MRI
programmes, and growing awareness and expertise in the
field.
In his role as Chief Medical
Advisor, Dr. Hall will assist in guiding Polarean's clinical
development strategy and medical education initiatives with fellow
clinicians and professional societies. He will leverage his
experience while maintaining his clinical pulmonology practice,
providing valuable insights to help Polarean address unmet medical
needs in pulmonary care.
Dr. Hall received his medical degree
from the University of Kansas School of Medicine and completed his
residency in Internal Medicine and fellowship training in Pulmonary
and Critical Care at Washington University School of Medicine in
St. Louis. He serves as a peer-reviewer for many prestigious
journals, such as Academic Radiology and The American Journal of
Respiratory and Critical Care Medicine.
Christopher
von Jako, Ph.D, CEO of Polarean, said: "I am delighted to welcome Dr. Hall to
Polarean as our new Chief Medical Advisor. As a leading expert in
pulmonary medicine as well as a champion of our Xenon MRI
technology platform, Dr. Hall is a perfect fit for the Company. His
appointment represents a significant step in growing the Polarean
team as we look to
expand Xenon MRI to
more clinical and research sites."
Chase Hall, M.D.,
CMA of Polarean, said: "For several years, I have been deeply
interested in the potential of Xenon MRI to assist pulmonary
clinicians and the patients we treat. There is a significant unmet
need in pulmonary medicine for imaging technology that can better
characterise disease, monitor response to therapy, and guide
interventional procedures. I am excited to join Polarean to help
guide the clinical development and implementation of this unique
technology in pulmonary medicine."
Enquiries:
Polarean
Imaging plc
|
www.polarean.com
/ www.polarean-ir.com
|
Christopher von Jako, Ph.D, Chief Executive
Officer
|
Via Walbrook PR
|
Charles Osborne, Chief Financial
Officer
|
|
|
|
Stifel (NOMAD
and Sole Corporate Broker)
|
+44 (0)20 7710
7600
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
Walbrook
PR
|
Tel: +44 (0)20 7933
8780 or polarean@walbrookpr.com
|
Anna Dunphy / Phillip Marriage
|
Mob: +44 (0)7876 741
001 / +44 (0)7867 984 082
|
|
|
|
|
| |
About Polarean
Polarean is a revenue-generating
medical imaging technology company revolutionising pulmonary
medicine through direct visualisation of lung function by
introducing the power and safety of MRI to the respiratory
healthcare community. This community is in desperate need of modern
solutions to accurately assess lung function. The Company strives
to optimise lung health and prevent avoidable loss by illuminating
hidden disease, addressing the global unmet medical needs of more
than 500 million patients worldwide suffering from chronic
respiratory disease. Polarean is a leader in the field of
hyperpolarisation science and has successfully developed the first
and only hyperpolarised Xenon MRI inhaled contrast agent,
XENOVIEW™, which is now FDA-approved in the United States. Polarean
is dedicated to researching, developing, and commercialising
innovative imaging solutions with its non-invasive and
radiation-free pulmonary functional MRI platform. This
comprehensive drug-device platform encompasses the proprietary
Xenon gas blend, gas hyperpolarisation system, as well as software
and accessories, facilitating fully integrated modern respiratory
imaging operations. Founded in 2012, with offices in Durham, NC,
and London, United Kingdom, Polarean is committed to increasing
global awareness of and broad access to its XENOVIEW MRI technology
platform. For the latest news and information about Polarean,
please visit www.polarean.com.
XENOVIEW IMPORTANT
SAFETY INFORMATION
Indication
XENOVIEW™, prepared from the Xenon Xe 129 Gas Blend,
is a hyperpolarized contrast agent indicated for use with magnetic
resonance imaging (MRI) for evaluation of lung ventilation in
adults and pediatric patients aged 12 years and older.
Limitations of
Use
XENOVIEW has not been evaluated for use with lung
perfusion imaging.
CONTRAINDICATIONS
None.
Warnings and
Precautions
Risk of Decreased Image Quality from Supplemental
Oxygen: Supplemental oxygen administered simultaneously with
XENOVIEW inhalation can cause degradation of image quality. For
patients on supplemental oxygen, withhold oxygen inhalation for two
breaths prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic
gas such as XENOVIEW may cause transient hypoxemia in susceptible
patients. Monitor all patients for oxygen desaturation and symptoms
of hypoxemia and treat as clinically indicated.
Adverse
Reactions
Adverse Reactions in Adult Patients: The adverse
reactions (> one patient) in efficacy trials were oropharyngeal
pain, headache, and dizziness. Adverse Reactions in Pediatric
and Adolescent Patients: In published literature in pediatric
patients aged 6 to 18, transient adverse reactions were reported:
blood oxygen desaturation, heart rate elevation, numbness,
tingling, dizziness, and euphoria. In at least one published study
of pediatric patients aged 6 to 18 years, transient decrease in
SpO2% and transient increase in heart rate was reported following
hyperpolarized xenon Xe 129 administration. XENOVIEW is not
approved for use in pediatric patients less than 12 years of
age.
Please see full prescribing information at
www.XENOVIEW.net